Cardiac examination in children with Laron syndrome undergoing mecasermin therapy

Erol N., Yildiz M., Guven A., Yildirim A.

JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, vol.31, no.6, pp.675-679, 2018 (Peer-Reviewed Journal) identifier

  • Publication Type: Article / Article
  • Volume: 31 Issue: 6
  • Publication Date: 2018
  • Doi Number: 10.1515/jpem-2017-0473
  • Journal Name: JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.675-679

Abstract

Background: Laron syndrome (LS), which can be defined as primary growth hormone resistance or insensitivity, is a rare genetic disease inherited by an autosomal recessive trait. Although it is undistinguishable from growth hormone deficiency, LS has high levels of growth hormone, but insulin-like growth factor (IGF-1) cannot be synthesized. Mecasermin treatment is the only option for the patients who suffer from LS. This study aims to research cardiac findings of children with LS, who receive treatment with mecasermin.